Yantai Lannacheng Biotechnology Co., Ltd.

MALVERN, Penn., Jan 20, 2026, 20n Bio, a peptide discovery company, and Yantai Lannacheng Biotechnology Co., Ltd. (“Lannacheng”), a clinical-stage radiopharmaceutical company, today announced a long-term strategic partnership to accelerate the development of next-generation Radionuclide Drug Conjugates (RDCs). The collaboration brings together 20n Bio’s high-throughput peptide discovery platform and Lannacheng’s radiopharmaceutical R&D, clinical translation, and manufacturing capabilities to advance precision oncology programs with the potential for improved efficacy and safety. RDCs are designed to deliver therapeutic radionuclides to tumors using targeting ligands that recognize tumor-associated antigens. By concentrating radiation in diseased tissue, RDCs aim to maximize anti-tumor activity while limiting exposure to healthy organs. In addition, radionuclide payloads can create a “bystander effect,” damaging neighboring tumor cells and components of the tumor microenvironment even when target expression is heterogeneous - an attribute that may help address resistance and broaden patient benefit. RDCs also support theranostic strategies, pairing diagnostic imaging with targeted radiotherapy to guide patient selection and treatment decisions. 20n Bio has built an in-house high-throughput experimental screening system and a topologically diverse cyclic peptide library comprising up to 10 trillion sequences. The platform enables rapid identification of cyclic peptide ligands with strong binding profiles and developability characteristics, followed by systematic optimization tailored to RDC applications. In 2025, 20n Bio was selected to Bayer Co.Lab, underscoring the industry recognition of its approach and its potential for global collaboration. “Lannacheng is an outstanding partner with deep expertise across radiopharmaceutical discovery and development,” said Dr. Mingfu Zhu, Founder and Chief Executive Officer of 20n Bio. “By combining our high-throughput cyclic peptide ligand engine with Lannacheng’s radiopharmaceutical capabilities, we intend to accelerate the creation of RDC programs that are more precise, more effective, and potentially safer. We believe this partnership can help expand the reach of targeted radiotherapy and bring meaningful new options to patients.” “RDCs are emerging as a major modality in oncology, and ligand innovation will be central to improving performance,” said Xiaoming Wu, General Manager of Lannacheng. “We are excited to work with 20n Bio to integrate their cyclic peptide discovery and optimization platform with our radiopharmaceutical technology stack, industrialization capabilities, and global partnership network. Together, we aim to advance differentiated RDC candidates and accelerate their translation toward clinical and commercial impact.” About 20n Bio 20n Bio is a venture-backed biotechnology company focused on the discovery of cyclic peptide therapeutics. The company’s mission is to develop peptide medicines through high-throughput screening and chemical optimization to address unmet medical needs. 20n Bio has established a proprietary cyclic peptide discovery platform capable of screening libraries containing up to 10 trillion peptide sequences. About Yantai Lannacheng Biotechnology Co., Ltd. Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of radiopharmaceuticals for integrated cancer diagnosis and therapy. The company’s R&D engine spans target validation, radionuclide selection, and linker design, supported by proprietary pharmacokinetic engineering technologies and dual-target drug development capabilities to advance next-generation radiopharmaceutical candidates. With end-to-end integration supported by its controlling shareholder, Dongcheng Pharmaceutical - including R&D resources, a stable supply of medical radioisotopes, and GMP manufacturing capacity under construction in Yantai - Lannacheng aims to improve continuity and scalability and accelerate innovation in radiopharmaceutical development.

Plus, news about Harbour BioMed, Omeros, Gilead, Repare Therapeutics, Vaccinex and Foresee Pharmaceuticals. 💵 ASK Pharm nabs China rights to pan-RAS inhibitor: ASK Pharm, also known as Jiangsu Aosaikang Pharmaceutical, will pay US and China-based biotech Adlai Nortye $20 million in upfront and near-term payments in a deal worth up to $230 million total. In exchange, ASK Pharm gets rights to the pan-RAS (ON) inhibitor AN9025 in mainland China, Hong Kong and Macao. — Lei Lei Wu 📑 Unicycive heads back to FDA with kidney disease drug: The California biotech has resubmitted its drug, known as oxylanthanum carbonate, to the FDA for the treatment of elevated levels of phosphate in patients with chronic kidney disease. The FDA rejected the drug in June over manufacturing problems. — Lei Lei Wu 🤝Harbour BioMed inks radionuclide deal: The 9-year-old biotech will work with Yantai Lannacheng Biotechnology to develop new radionuclide drug conjugates. The companies didn’t reveal the financial terms of the long-term deal . But a couple weeks prior, Harbour BioMed announced a separate partnership with Bristol Myers Squibb that will give the biotech $90 million upfront. — Nicole DeFeudis 💉 FDA approves Omeros’ Yartemlea : The Seattle-based biotech said Yartemlea (narsoplimab) is the first approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or a serious blood-clotting complication. Omeros did not disclose pricing in a Wednesday press release. It anticipates an approval decision by the European Medicines Agency in mid-2026. — Andy Dunn 💰 Gilead to acquire Repare Therapeutics’ cancer drug: The pharma giant has paid $25 million upfront to acquire the clinical-stage drug, a polymerase theta ATPase inhibitor called RP-3467 that’s currently in a Phase 1 trial. Gilead will pay an additional $5 million “upon completion of specified technology transfer activities,” according to a Dec. 24 press release. That cash is expected to boost the payout to shareholders of Repare, which agreed in November to be acquired by the privately held nonprofit biotech XenoTherapeutics. — Andy Dunn 🧠 Vaccinex gets $60 million for Alzheimer’s work: The funding, which comes from an entity established by an existing investor, will allow Vaccinex to run an enlarged Phase 2b study for its drug candidate pepinemab. In return, the investment entity will get half of future proceeds from a development partner or licensee of pepinemab for neurological indications and 25% of proceeds related to other indications. — Nicole DeFeudis 💉 Foresee’s Phase 3 success in kids experiencing early puberty: The Taiwan- and US-based company’s drug, called leuprolide mesylate, is a GnRH agonist that was tested as a twice-yearly injection in children with a condition called central precocious puberty. The company says it plans to discuss submitting a new drug application by mid-2026. Foresee most recently won approval for leuprolide mesylate at a different dosing strength and interval to treat advanced prostate cancer, which is marketed as Camcevi. — Andy Dunn

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs). Compared with conventional radiotherapy, RDCs utilize tumor antigen–specific ligands to deliver radionuclides directly to tumor lesions for targeted radiotherapy, thereby effectively reducing damage to surrounding healthy tissues. In contrast to antibody–drug conjugates (ADCs), the radionuclides in RDCs can also exert cytotoxic effects on neighboring tumor cells and the tumor microenvironment, even if those cells do not express the target antigen. This mechanism offers a potential advantage in overcoming tumor heterogeneity and drug resistance. In addition, this technology holds the potential to achieve theranostics—integrating both diagnosis and treatment. With its advanced technology platforms and deep expertise, Harbour BioMed has built a solid foundation in antibody discovery and development. The company's proprietary Harbour Mice® platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanization. The HCAb technology, in particular, produces unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapeutics. In the development of RDCs, fully human antibodies—characterized by low immunogenicity, superior tissue penetration, and high specificity and stability—can significantly enhance the efficiency of targeted delivery, thereby improving therapeutic efficacy while effectively reducing drug-related toxicity and side effects. Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of integrated theranostic radiopharmaceuticals for oncology. The company's R&D engine, enhanced by its proprietary pharmacokinetic optimization and dual-targeting drug development platforms, combines target validation, radioisotope selection, and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates. Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable, and rapidly innovating radiopharmaceutical pipeline. Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: "We are very pleased to establish a long-term strategic collaboration with Lannacheng to jointly advance the development of next-generation RDCs. Harbour BioMed is committed to providing efficient and highly differentiated antibody solutions for innovative therapies through our globally leading Harbour Mice® fully human antibody platform. This collaboration will deeply integrate Harbour BioMed's expertise in antibody discovery with Lannacheng's strengths in radiopharmaceutical R&D and commercialization, accelerating the development of more precise, effective and safe cancer therapies and bringing new hope to patients worldwide." Wu Xiaoming, General Manager of Lannacheng, stated: "We are delighted to establish a long-term strategic collaboration with Harbour BioMed to jointly advance the R&D and translation of next-generation radiopharmaceuticals. Lannacheng is committed to leveraging our systematic radiopharmaceutical technology platform, comprehensive industrial capabilities, and global collaboration network to provide efficient, innovative, and differentiated integrated solutions for tumor diagnosis and treatment. This collaboration will fully combine Lannacheng's strengths in radiopharmaceutical R&D and commercialization and Harbour BioMed's deep expertise in antibody discovery. Together, we aim to accelerate the development of more precise, effective, and safe cancer treatment therapies, bringing new hope to patients worldwide." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICA™) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICA™ with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit . About Yantai Lannacheng Biotechnology Co., Ltd. Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of integrated theranostic radiopharmaceuticals for oncology. The company's R&D engine, enhanced by its proprietary pharmacokinetic optimization and dual-targeting drug development platforms, combines target validation, radioisotope selection, and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates. Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable, and rapidly innovating radiopharmaceutical pipeline. SOURCE Harbour BioMed 21% more press release views with Request a Demo